Ποια είναι η τιμή για Formosa Pharmaceuticals, Inc. (6838)

Η τιμή για Formosa Pharmaceuticals, Inc. (6838) είναι $0.79338575

Ποια είναι η κεφαλαιοποίηση αγοράς για Formosa Pharmaceuticals, Inc. (6838)

Η κεφαλαιοποίηση αγοράς για Formosa Pharmaceuticals, Inc. (6838) είναι $119.78M

Formosa Pharmaceuticals, Inc. (6838) Έσοδα

Formosa Pharmaceuticals, Inc., a biopharmaceutical firm situated in Taipei City, Taiwan, is actively engaged in both late-preclinical and early clinical development stages. Its core focus lies in pioneering therapeutic candidates across ophthalmology, oncology, and anti-infective domains. Among its key investigational assets is APP13007, an ophthalmic nanosuspension, currently progressing through Phase III trials for managing post-surgical discomfort and inflammation of the eye. The company's portfolio also encompasses TSY-0110, designed as an antibody-drug conjugate, and TSY-0210, an antibiotic targeting resilient drug-resistant infections. Further compounds under development include APP13002, a topical antibiotic intended for ocular infections like blepharitis, and MPT0E028, a novel pan-histone deacetylase inhibitor being explored for solid malignancies such as hepatomas and colorectal cancer, in addition to lung fibrosis. Additionally, Formosa Pharmaceuticals maintains a collaborative partnership with Eyenovia, Inc., dedicated to advancing innovative ophthalmic treatments. Established in 2010, the company is headquartered in Taiwan's capital.

Έτος	Έσοδα	Αλλαγή
Δεν υπάρχουν αρκετά δεδομένα για τις παρεχόμενες ημερομηνίες.

Έτος

Έσοδα

Αλλαγή

Δεν υπάρχουν αρκετά δεδομένα για τις παρεχόμενες ημερομηνίες.

Εταιρεία	Έσοδα	Διαφορά Εσόδων	Χώρα
Vertex Pharmaceuticals Incorporated VRTX.US	$12.62B	-	US
Argenx SE ARGX.US	$6.02B	-	NL
Moderna, Inc. MRNA.US	$2.23B	-	US
CSL Limited CSL.AX	$15.74B	-	AU
Lonza Group AG LONN.SW	-	-	CH

Εταιρεία

Έσοδα

Διαφορά Εσόδων

Χώρα